美國NovaBios埃博拉病毒快速檢測試紙（膠體金法）

廣州健侖生物科技有限公司

本司長期供應(yīng)埃博拉病毒檢測試劑盒，其主要品牌包括美國NovaBios、廣州創(chuàng)侖等CDC使用的產(chǎn)品，試劑盒的實(shí)驗(yàn)方法包括膠體金方法、ELISA方法、PCR方法等。

歡迎咨詢

歡迎咨詢2042552662

埃博拉病毒IgM、IgG、ELISA檢測試劑、埃博拉快速檢測試劑盒、

埃博拉病毒核酸檢測試劑盒（熒光探針PCR）

西非工作、旅游埃博拉檢測試劑盒

美國CDC使用的埃博拉診斷試劑——美國的NovaBios

美國NovaBios 埃博拉病毒快速檢測試紙（膠體金法）

【埃博拉簡介】

埃博拉（Ebola virus）又譯作伊波拉病毒。是一種十分罕見的病毒，1976年在蘇丹南部和剛果（金）（舊稱扎伊爾）的埃博拉河地區(qū)發(fā)現(xiàn)它的存在后，引起醫(yī)學(xué)界的廣泛關(guān)注和重視，“埃博拉”由此而得名。是一個(gè)用來稱呼一群屬于纖維病毒科埃博拉病毒屬下數(shù)種病毒的通用術(shù)語。是一種能引起人類和靈長類動(dòng)物產(chǎn)生埃博拉出血熱的烈性傳染病病毒，有很高的死亡率，在50%至90%之間，致死原因主要為中風(fēng)、心肌梗塞、低血容量休克或多發(fā)性器官衰竭。

埃博拉出血熱（EBHF）是由一種絲狀病毒感染導(dǎo)致的急性出血性、動(dòng)物源性傳染病。1976年，埃博拉出血熱在非洲的蘇丹和扎伊爾暴發(fā)，病死率高達(dá)50% ～ 90% 。因該病始發(fā)于扎伊爾北部的埃博拉河流，并在該區(qū)域嚴(yán)重流行，故命名為埃博拉病毒，其形態(tài)學(xué)、致病性等與馬爾堡病毒相似，但免疫原性有所區(qū)別。

【產(chǎn)品介紹】

該產(chǎn)品是世界衛(wèi)生組織（WHO）*個(gè)批準(zhǔn)用于埃博拉病毒檢測的診斷試劑卡。不需要借助其他實(shí)驗(yàn)儀器設(shè)備，只需要采取幾滴血清、血漿、血液樣品，既可以檢測，并在15分鐘內(nèi)就可以得知結(jié)果是否感染埃博拉病毒。該產(chǎn)品具有靈敏度高、操作方便、實(shí)驗(yàn)時(shí)間短等特點(diǎn)。

美國NovaBios

檢查方法埃博拉
埃博拉病毒是高度危險(xiǎn)的病原體，必須在專門的實(shí)驗(yàn)設(shè)施內(nèi)進(jìn)行病毒的分離與鑒定。在非洲疫區(qū)主要通過檢測埃博拉病毒的特異性IgM和IgG抗體以及檢查病毒抗原或核酸等進(jìn)行診斷。
病毒特異性抗體的檢查
病人血液中的病毒特異性IgM抗體在發(fā)病后2～9天出現(xiàn)，持續(xù)存在到發(fā)病后1～6個(gè)月；IgG抗體在發(fā)病后6～18天出現(xiàn)，持續(xù)存在到發(fā)病后2年以上。用基因工程方法制備出的病毒核心蛋白羧基端多肽為抗原，建立的檢測埃博拉病毒IgG抗體的ELISA方法，特異性和敏感性較高。但對(duì)于部分急性期血清中特異性抗體滴度很低的患者，應(yīng)同時(shí)進(jìn)行病毒抗原或核酸的檢測。
病毒特異性抗原和核酸的檢查
已經(jīng)證實(shí)檢測埃博拉病毒抗原與檢測病毒核酸的*性幾乎達(dá)到100%，敏感度很高。并且，用?射線照射標(biāo)本并滅活病毒后，再檢測病毒抗原或RNA時(shí)，實(shí)驗(yàn)安全性增高，且實(shí)驗(yàn)結(jié)果也不受顯著影響。埃博拉
預(yù)防措施埃博拉
疫苗研制
2006年2月美國國家衛(wèi)生研究院負(fù)責(zé)人加里·納貝爾稱，
埃博拉病毒
埃博拉病毒
預(yù)防致命性埃博拉病毒的疫苗已經(jīng)通過了zui初的人類安全檢測，其令人充滿希望的跡象表明，這種疫苗能使人類免受此病的感染。埃博拉
已經(jīng)有21人接受了早期測試的試驗(yàn)性疫苗。不過納貝爾提醒說，仍需進(jìn)行更多的研究以證實(shí)這種疫苗是否成功。
納貝爾和研究中心的同事從含有3個(gè)埃博拉蛋白質(zhì)的DNA中研發(fā)出疫苗。他們說，這種疫苗能令侯子對(duì)埃博拉有免疫力。疫苗不僅能抑制這種病的傳播，還能保護(hù)醫(yī)生、護(hù)士和動(dòng)物飼養(yǎng)員，以防患于未然。埃博拉

美國NovaBios

我司還提供其它進(jìn)口或國產(chǎn)試劑盒：登革熱、瘧疾、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲病、違禁品濫用、肺炎球菌、軍團(tuán)菌等試劑盒以及日本生研細(xì)菌分型診斷血清、德國SiFin診斷血清、丹麥SSI診斷血清等產(chǎn)品。

想了解更多的NovaBios產(chǎn)品及服務(wù)請(qǐng)掃描下方二維碼：

【公司名稱】 廣州健侖生物科技有限公司
【市場部】    楊永漢

【】 
【騰訊  】 2042552662
【公司地址】 廣州清華科技園創(chuàng)新基地番禺石樓鎮(zhèn)創(chuàng)啟路63號(hào)二期2幢101-103室

Epidemic area infection, off-site disease: So far, the United States, Britain, Switzerland reported input cases, are popular areas travel, participate in the diagnosis and treatment of patients or participate in investigative researchers. Not popular. Ebola
Check the method of Ebola
Ebola virus is a highly dangerous pathogen, must be in a special laboratory facilities for virus isolation and identification. In the African epidemic area mainly through the detection of Ebola virus specific IgM and IgG antibodies and check the virus antigen or nucleic acid for diagnosis.
Virus-specific antibody
The virus-specific IgM antibody in the blood of the patient appeared 2 to 9 days after the onset of the disease, 1 to 6 months after the onset of the disease; IgG antibody appeared 6 to 18 days after the onset, persisted after the onset of more than 2 years. The ELISA method for the detection of Ebola virus IgG antibody was established by the method of genetic engineering, and the specificity and sensitivity were high. However, in some acute phase serum specific antibody titers in patients with low, should also be the virus antigen or nucleic acid detection.
Virus-specific antigens and nucleic acids
It has been shown that detection of Ebola virus antigen and detection of viral nucleic acid consistency is almost 100%, high sensitivity. In addition, when the virus was irradiated with the radiation and the virus was inactivated, and the virus antigen or RNA was detected, the experimental safety was increased and the experimental results were not significantly affected. Ebola
Preventive measures Ebola
Vaccine development
In February 2006, Gary Naber, head of the National Institutes of Health,
Ebola virus
Ebola virus
The vaccine that prevents fatal Ebola virus has passed the initial human safety test, and its promising signs suggest that the vaccine can protect humans from the disease. Ebola
Twenty-one have been tested for early trials of experimental vaccines. But Naber reminded that more research was needed to confirm whether the vaccine was successful.
Naber and colleagues at the research center developed a vaccine from DNA containing three Ebola proteins. They say that this vaccine can make Hou child immune to Ebola. Vaccines can not only prevent the spread of the disease, but also to protect doctors, nurses and animal breeders to prevent trouble. Ebola
On August 9, 2014, China announced that it had acquired the Ebola virus antibody gene and had the ability to develop diagnostic reagents for the timely detection of Ebola virus, which surprised the world. At the same time, the World Health Organization officials also reminded countries to pay attention to China's response to the epidemic in the rich experience. Ebola